SCHEDULE 13D/A: Onconetix Officer Christian Bruhlmann Amends Ownership Disclosure, Reports 4.20% Stake After RSU Grant and Lock-Up Expiry

Christian Bruhlmann, Chief Strategy Officer of Onconetix, Inc., filed an amended Schedule 13D to update his beneficial ownership to 4.20% of common stock, reflecting a recent RSU grant and the expiration of a lock-up agreement.

Summary

• Christian Bruhlmann, Chief Strategy Officer of Onconetix, Inc., filed an Amendment No. 1 to his Schedule 13D, updating his beneficial ownership.
• He beneficially owns an aggregate of 611,372 shares of Onconetix, Inc. common stock, which represents 4.20% of the class.
• This total includes 433,910 shares of common stock and 177,462 shares issuable upon settlement of fully vested Restricted Stock Units (RSUs).
• The initial shares were acquired pursuant to a Share Exchange Agreement dated December 15, 2023, as part of the Issuer's acquisition of Proteomedix AG (PMX Acquisition).
• His 171,204 shares of Series B Convertible Preferred Stock automatically converted into 428,010 common shares on September 24, 2024, following stockholder approval on September 5, 2024, and a 1-for-40 reverse stock split.
• He received the 177,462 fully vested RSUs on December 20, 2024, in exchange for options to purchase shares of Proteomedix AG.
• A Lock-Up Agreement, which restricted the transfer of his shares, ended on December 31, 2024.
• Christian Bruhlmann ceased to be a beneficial holder of more than 5% of the Issuer's Common Stock on December 31, 2024.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It's a routine ownership update reflecting the integration of an acquisition and compensation. The increase in total shares held by the CSO is positive, while the drop below 5% ownership threshold is a technicality due to the RSU grant and overall share count, not necessarily a negative sentiment from the insider.

Positives

• The grant of 177,462 fully vested Restricted Stock Units (RSUs) to the Chief Strategy Officer indicates continued compensation and alignment of management interests with shareholder value.
• The successful conversion of Series B Convertible Preferred Stock into common stock, following stockholder approval and a reverse stock split, demonstrates the company's ability to execute corporate actions related to the Proteomedix acquisition.

Negatives

• Christian Bruhlmann, the Chief Strategy Officer, ceased to be a beneficial holder of more than 5% of the Issuer's Common Stock on December 31, 2024, which could be perceived as a slight reduction in a key insider's proportional stake, although the total number of shares held increased due to the RSU grant.

Risks

• The Lock-Up Agreement restricting the transfer of shares held by the Reporting Person expired on December 31, 2024, which could potentially lead to increased selling pressure if the Reporting Person decides to dispose of shares, although no such intention is stated.

Future Outlook

The filing primarily details past ownership changes and does not provide specific forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the Reporting Person's role as Chief Strategy Officer.

Management Comments

• "The Reporting Person serves as the Chief Strategy Officer of the Issuer and, as a result, may be asked to discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others."
• "Other than in connection with the prior PMX Acquisition and except as may be set forth herein, the Reporting Person has no current intention, plans or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D."

Industry Context

This filing is a routine ownership disclosure for an insider following corporate actions and RSU grants. It does not provide broader industry context or trends, focusing solely on the beneficial ownership of Christian Bruhlmann in Onconetix, Inc. post-acquisition of Proteomedix AG.

Corporate Governance

Related Party Transactions

• The Reporting Person, Christian Bruhlmann, as an officer of Onconetix, Inc. and a former holder of Proteomedix AG equity interests, received shares and RSUs as part of the Share Exchange Agreement and subsequent compensation, which constitutes a transaction with a related party (an officer and former owner of an acquired entity).

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a key insider's ownership stake and the corporate actions (preferred stock conversion, reverse split, RSU grant) that impacted it. The expiration of the lock-up agreement could potentially increase the float of shares available for trading, though no immediate selling intent is indicated.
• Employees: The grant of fully vested RSUs to the Chief Strategy Officer is a form of compensation, aligning his interests with the company's performance and potentially setting a precedent for other employee equity incentives.
• Management: The Chief Strategy Officer's continued significant ownership stake and his role in discussing strategic matters reinforce management's commitment and involvement in the company's direction.

Next Steps

• The Reporting Person, as Chief Strategy Officer, may continue to discuss matters related to the Issuer's operations and strategy.

Key Dates

Recommendation

Keywords

Onconetix Inc., Christian Bruhlmann, Schedule 13D, Beneficial Ownership, Common Stock, Restricted Stock Units, RSUs, Share Exchange Agreement, Proteomedix AG, PMX Acquisition, Series B Convertible Preferred Stock, Stockholder Approval, Reverse Stock Split, Lock-Up Agreement, Insider Ownership, Corporate Governance, SEC Filing